Asston Pharmaceuticals Limited (BOM:544445)
India · Delayed Price · Currency is INR 62.45
-1.79 (-2.79%)
At close: Jul 27, 2026
Asston Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 12.91 | 1.99 | 0.06 | 1.24 | 1.37 |
Cash & Short-Term Investments | 12.91 | 1.99 | 0.06 | 1.24 | 1.37 |
Cash Growth | 548.32% | 3010.94% | -94.83% | -9.58% | 321.05% |
Accounts Receivable | 365.68 | 245.49 | 161.52 | 86.09 | 64.03 |
Receivables | 365.68 | 245.49 | 161.52 | 86.09 | 67.39 |
Inventory | 7.67 | 7.17 | 14.39 | 15.01 | 5.03 |
Other Current Assets | 19.51 | 15.53 | 7.39 | 4.6 | - |
Total Current Assets | 405.76 | 270.19 | 183.36 | 106.93 | 73.79 |
Property, Plant & Equipment | 106.94 | 9.56 | 10.91 | 11.31 | 9.18 |
Long-Term Deferred Tax Assets | - | 0.23 | - | - | - |
Other Long-Term Assets | - | 1.25 | 8.34 | 6.73 | 0 |
Total Assets | 516.46 | 281.23 | 202.6 | 136.94 | 94.91 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 57.58 | 58.62 | 58.1 | 55.4 | 45.3 |
Accrued Expenses | 1.8 | 12.1 | 6.67 | 4.73 | 3.33 |
Short-Term Debt | 15.55 | 37.29 | 45.54 | 31.31 | 23.13 |
Current Portion of Long-Term Debt | - | 12.72 | 6.39 | 2.95 | 0.56 |
Current Income Taxes Payable | - | 17.87 | 3.62 | 3.48 | 0.21 |
Other Current Liabilities | 14.97 | 11.29 | 0.25 | - | 3.03 |
Total Current Liabilities | 89.89 | 149.88 | 120.58 | 97.88 | 75.56 |
Long-Term Debt | 35.53 | 22.57 | 16.27 | 18.19 | 9.41 |
Pension & Post-Retirement Benefits | 1.59 | 1.61 | 1.6 | 0.69 | 0.49 |
Long-Term Deferred Tax Liabilities | 0.83 | - | 0.24 | 0.33 | 0.17 |
Other Long-Term Liabilities | 0 | -0 | -0 | - | - |
Total Liabilities | 127.83 | 174.05 | 138.68 | 117.08 | 85.62 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 85.12 | 62.71 | 7.84 | 7 | 7 |
Additional Paid-In Capital | - | - | 29.62 | - | - |
Retained Earnings | 303.5 | 44.46 | 26.46 | 12.86 | 2.3 |
Comprehensive Income & Other | -0 | -0 | - | - | -0.01 |
Shareholders' Equity | 388.62 | 107.18 | 63.93 | 19.86 | 9.29 |
Total Liabilities & Equity | 516.46 | 281.23 | 202.6 | 136.94 | 94.91 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 51.08 | 72.57 | 68.2 | 52.45 | 33.1 |
Net Cash (Debt) | -38.17 | -70.58 | -68.14 | -51.21 | -31.73 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -4.86 | -11.25 | -12.17 | -9.15 | -333.35 |
Filing Date Shares Outstanding | 8.91 | 6.27 | 6.27 | 0.7 | 0.1 |
Total Common Shares Outstanding | 8.91 | 6.27 | 6.27 | 0.7 | 0.1 |
Working Capital | 315.87 | 120.31 | 62.78 | 9.05 | -1.77 |
Book Value Per Share | 43.61 | 17.09 | 10.19 | 28.37 | 97.68 |
Tangible Book Value | 388.62 | 107.18 | 63.93 | 19.86 | 9.29 |
Tangible Book Value Per Share | 43.61 | 17.09 | 10.19 | 28.37 | 97.68 |
Buildings | - | - | 9.32 | 9.32 | 9.32 |
Machinery | - | 10.95 | 2.73 | 2.63 | 0.12 |